Search bioRxiv⌕ Search

Biology subjects

Tatonetti, N. P.

Publications and source records attributed to Tatonetti, N. P..

10 recordsLinked to original sources

BioMADE: Predicting Torsades de Pointes from molecular structures through biologically informed representations

Drug-induced arrhythmias, particularly Torsades de Pointes (TdP), pose a significant risk to patient safety and can sometimes have life-threatening outcomes. They remain a major concern in drug development and regulation. Machine learning (ML) has become a powerful tool for analyzing complex biological and chemical datasets, enabling researchers to identify subtle patterns that differentiate safe compounds from those likely to cause dangerous cardiac effects. However, most existing in silico approaches do not sufficiently incorporate biological elements, relying heavily on chemical and structural properties or on computationally expensive simulations. Here, we introduce BioMADE, a novel ML framework that harnesses small-molecule-protein activity profiles from publicly available datasets to predict TdP risk without requiring exhaustive mechanistic annotation. Activity data from ChEMBL were used to train individual models for each gene, which predict activity values for any given compound. A curated set of arrhythmia-relevant genes was then used to construct a latent biological embedding (BioMADE embedding) for each molecule. We validated the performance of these features in distinguishing biological elements such as ATC3 class, showing superior classification performance compared with representations such as Molformer (lacks biological information) and MACCS (limited chemical properties) (0.85 AUROC vs 0.81 and 0.73, respectively). BioMADE representations served as input to a support vector machine classifier to discriminate TdP-inducing drugs from safe compounds. BioMADE achieved an AUROC of 0.89 in internal validation, indicating strong predictive performance. Against state-of-the-art models such as ADMEThyst, BioMADE achieved an AUROC of 0.74 on ADMEThysts validation set (vs. 0.72 for ADMEThyst). When we combined both approaches, the AUROC reached 0.77. These results demonstrate that BioMADE provides a scalable, biology-informed, and generalizable approach for predicting drug-induced toxicities. By integrating protein activity profiles into toxicology modeling, our framework highlights the critical role of human biology in adverse drug reaction prediction, an aspect often overshadowed by purely chemical or structural descriptors.

bioinformatics↗

Phenotype projections accelerate biobank-scale GWAS

Understanding the genetic basis of complex disease is a critical research goal due to the immense, worldwide burden of these diseases. Pan-biobank genome-wide association studies (GWAS) provide a powerful resource in complex disease genetics, generating shareable summary statistics on thousands of phenotypes. Biobank-scale GWAS have two notable limitations: they are resource-intensive to compute and do not inform about hand-crafted phenotype definitions, which are often more relevant to study. Here we present Indirect GWAS, a summary-statistic-based method that addresses these limitations. Indirect GWAS computes GWAS statistics for any phenotype defined as a linear combination of other phenotypes. Our method can reduce runtime by an order of magnitude for large pan-biobank GWAS, and it enables ultra-rapid (roughly one minute) GWAS on hand-crafted phenotype definitions using only summary statistics. Overall, this method advances complex disease research by facilitating more accessible and cost-effective genetic studies using large observational data.

genetics↗

Mural norrin/β-catenin signaling regulates Lama2 expression to promote neurovascular unit assembly

Neurovascular unit (NVU) assembly and barrier maturation rely on vascular basement membrane (vBM) composition. Laminins, a major vBM component, are critical for these processes, yet which signaling pathway(s) regulate their expression remains unknown. Here we show that mural cells have active Norrin/{beta}-catenin signaling during central nervous system development. Bulk RNA sequencing and validation using P10 and P14 wild-type versus Apcdd1-/- retinas reveal that Lama2 (Laminin-2 chain) mRNA and protein levels are increased in mutant vasculature undergoing higher Norrin/{beta}-catenin signaling. Mural cells are the main source of Lama2, and {beta}-catenin activation induces Lama2 expression in mural cells in vitro. Markers of mature astrocytes including Aquaporin-4 (a water channel in astrocyte endfeet) and Integrin-6 (a laminin receptor) are upregulated in Apcdd1-/- retinas following higher Lama2 vBM deposition. Thus, the Norrin/{beta}-catenin pathway regulates Lama2 expression in mural cells to promote NVU assembly and neurovascular barrier maturation. SUMMARYBiswas et al., demonstrate that Norrin/{beta}-catenin signaling is active in CNS mural cells and regulates Lama2 deposition in the vascular basement membrane, promoting neurovascular unit assembly and blood-CNS barrier maturation.

developmental biology↗

Transfer learning from simulations improves the classification of OCT images of glandular epithelia

Esophageal adenocarcinoma (EAC) is a rare but lethal cancer with rising incidence in several global hotspots including the United States. The five-year survival rate for patients diagnosed with advanced disease can be as low as 5% in EAC, making early detection and preventive intervention crucial. The current standard of care for EAC targets patients with Barretts esophagus (BE), the main precursor to EAC and a relatively common condition in adults with chronic acid reflux disease. Preventive care for EAC requires repeated surveillance endoscopies of BE patients with biopsy sampling, and can be intrusive, error-prone, and costly. The integration of minimally-invasive subsurface tissue imaging in the current standard of care can reduce the need for exhaustive tissue sampling and improve the quality of life in BE patients. Effective adoption of subsurface imaging in EAC care can be facilitated by computer-aided detection (CAD) systems based on deep learning. Despite their recent successes in lung and breast cancer imaging, the development of deep neural networks for rare conditions like EAC remains challenging due to data scarcity, heavy bias in existing datasets toward non-cases, and uncertainty in image labels. Here we explore the use of synthetic datasets-specifically data derived from simulations of optical back-scattering during imaging- in the development of CAD systems based on deep learning. As a proof of concept, we studied the binary classification of esophageal OCT into normal squamous and glandular mucosae, typical of BE. We found that deep convolutional networks trained on synthetic data had improved performance over models trained on clinical datasets with uncertain labels. Model performance also improved with dataset size during training on synthetic data. Our findings demonstrate the utility of transfer from simulations to real data in the context of medical imaging, especially in the severely data-poor regime and when significant uncertainty in labels are present, and motivate further development of transfer learning from simulations to aid the development of CAD for rare malignancies.

bioinformatics↗

EdiTyper: a high-throughput tool for analysis of targeted sequencing data from genome editing experiments

Genome editing experiments are generating an increasing amount of targeted sequencing data with specific mutational patterns indicating the success of the experiments and genotypes of clonal cell lines. We present EdiTyper, a high-throughput command line tool specifically designed for analysis of sequencing data from polyclonal and monoclonal cell populations from CRISPR gene editing. It requires simple inputs of sequencing data and reference sequences, and provides comprehensive outputs including summary statistics, plots, and SAM/BAM alignments. Analysis of simulated data showed that EdiTyper is highly accurate for detection of both single nucleotide mutations and indels, robust to sequencing errors, as well as fast and scalable to large experimental batches. EdiTyper is available in github (https://github.com/LappalainenLab/edityper) under the MIT license.

genomics↗

Host, Viral, and Environmental Transcriptome Profiles of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused thousands of deaths worldwide, including >18,000 in New York City (NYC) alone. The sudden emergence of this pandemic has highlighted a pressing clinical need for rapid, scalable diagnostics that can detect infection, interrogate strain evolution, and identify novel patient biomarkers. To address these challenges, we designed a fast (30-minute) colorimetric test (LAMP) for SARS-CoV-2 infection from naso/oropharyngeal swabs, plus a large-scale shotgun metatranscriptomics platform (total-RNA-seq) for host, bacterial, and viral profiling. We applied both technologies across 857 SARS-CoV-2 clinical specimens and 86 NYC subway samples, providing a broad molecular portrait of the COVID-19 NYC outbreak. Our results define new features of SARS-CoV-2 evolution, nominate a novel, NYC-enriched viral subclade, reveal specific host responses in interferon, ACE, hematological, and olfaction pathways, and examine risks associated with use of ACE inhibitors and angiotensin receptor blockers. Together, these findings have immediate applications to SARS-CoV-2 diagnostics, public health, and new therapeutic targets.

molecular biology↗

Predicting the genetic ancestry of 2.6 million New York City patients using clinical data

Ancestry is an essential covariate in clinical genomics research. When genetic data are available, dimensionality reduction techniques, such as principal components analysis, are used to determine ancestry in complex populations. Unfortunately, these data are not always available in the clinical and research settings. For example, electronic health records (EHRs), which are a rich source of temporal human disease data that could be used to enhance genetic studies, do not directly capture ancestry. Here, we present a novel algorithm for predicting genetic ancestry using only variables that are routinely captured in EHRs, such as self-reported race and ethnicity, and condition billing codes. Using patients that have both genetic and clinical information at Columbia University/ New York-Presbyterian Irving Medical Center, we developed a pipeline that uses only clinical data to predict the genetic ancestry of all patients of which more than 80% identify as other or unknown. Our ancestry estimates can be used in observational studies of disease inheritance, to guide genetic cohort studies, or to explore health disparities in clinical care and outcomes.

bioinformatics↗

cohorts: A Python package for clinical ‘omics data management

SummaryPrecision medicine uses patient clinical and molecular characteristics to personalize diagnosis and treatment. This emerging discipline integrates multi-modal data into large-scale studies of human disease to make accurate individual-level predictions. The success of these studies will depend on the generalizability of the results, the ability of other researchers and clinicians to replicate studies, and the understandability of the methods used. Tools for data management and standardization are needed to promote flexible, transparent, and reproducible analyses. Here we present cohorts, a python package facilitating clinical and biomarker data management to enhance standardization and reproducibility of clinical findings.\n\nAvailabilityThe python package cohorts is available at http://www.github.com/ngiangre/cohorts.\n\nCONTACTNPT2105@CUMC.COLUMBIA.EDU

bioinformatics↗

Comparative analysis of EHR-based stroke phenotyping methods, their applications, and interpretation

Background and PurposeAccurate identification of acute ischemic stroke (AIS) patient cohorts is essential for a wide range of clinical investigations. Automated phenotyping methods that leverage electronic health records (EHRs) represent a fundamentally new approach cohort identification. Unfortunately, the current generation of these algorithms is laborious to develop, poorly generalize between institutions, and rely on incomplete information. We systematically compared and evaluated the ability of several machine learning algorithms and case-control combinations to phenotype acute ischemic stroke patients using data from an EHR.\n\nMethodsUsing structured patient data from the EHR at a tertiary-care hospital system, we built machine learning models to identify patients with AIS based on 75 different case-control and classifier combinations. We then determined the models classification ability for AIS on an internal validation set, and estimated the prevalence of AIS patients across the EHR. Finally, we externally validated the ability of the models to detect self-reported AIS patients without AIS diagnosis codes using the UK Biobank.\n\nResultsAcross all models, we found that the mean area under the receiver operating curve for detecting AIS was 0.963{+/-}0.0520 and average precision score 0.790{+/-}0.196 with minimal feature processing. Logistic regression classifiers with L1 penalty gave the best performance. Classifiers trained with cases with AIS diagnosis codes and controls with no cerebrovascular disease diagnosis codes had the best average F1 score (0.832{+/-}0.0383). In the external validation, we found that the top probabilities from a model-predicted AIS cohort were significantly enriched for self-reported AIS patients without AIS diagnosis codes (65-250 fold over expected).\n\nConclusionsOur findings support machine learning algorithms as a way to accurately identify AIS patients without relying on diagnosis codes or using process-intensive manual feature curation. When a set of AIS patients is unavailable, diagnosis codes may be used to train classifier models. Our approach is potentially generalizable to other academic institutions and further external validation is needed.

bioinformatics↗

Predicting negative control drugs to support research in drug safety

The lack of high-quality reference data is a major limitation in drug safety and drug discovery science. Unreliable standards prohibit the use of supervised learning methods and make evaluation of algorithms difficult. While some data is available for positive examples (e.g. which drugs are associated with a side effect), there are no systematic resources of negative controls. To solve this issue, we introduced SIDERctrl, a computational method that ranks drugs based on the likelihood of not causing a side effect. We applied SIDERctrl to predict negative controls from unreported drugs of 890 side effects in SIDER. Our predictions decreased the false negative rate by one-third according to a validation study using AEOLUS data. Three sets of predicted negative controls by different thresholds of precision were provided, and can be accessed at http://tatonettilab.org/resources/negative-drugs.html. This new reference standard will be important in chemical biology, drug development, and pharmacoepidemiology.\n\nKEY POINTSO_LIThe lack of systematic resources providing negative control drugs limits the performance of existing research in drug safety.\nC_LIO_LIWe developed a novel method that integrated chemical and biological properties a drug and the target proteins to calculate the likelihood of the drug being negative control.\nC_LIO_LIWe applied our method to 890 side effects, and showed that our method significantly decreased the false negative rate of predictions.\nC_LI

pharmacology and toxicology↗